1. Home
  2. IP vs VTRS Comparison

IP vs VTRS Comparison

Compare IP & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Paper Company

IP

International Paper Company

N/A

Current Price

$35.57

Market Cap

21.5B

ML Signal

N/A

Logo Viatris Inc.

VTRS

Viatris Inc.

N/A

Current Price

$13.78

Market Cap

17.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IP
VTRS
Founded
1898
1961
Country
United States
United States
Employees
N/A
30000
Industry
Paper
Medicinal Chemicals and Botanical Products
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.5B
17.2B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
IP
VTRS
Price
$35.57
$13.78
Analyst Decision
Buy
Hold
Analyst Count
9
6
Target Price
$48.50
$11.83
AVG Volume (30 Days)
5.3M
9.3M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.79%
3.44%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,299,900,000.00
Revenue This Year
$7.71
$3.36
Revenue Next Year
$3.88
$1.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.56
$6.85
52 Week High
$56.64
$16.47

Technical Indicators

Market Signals
Indicator
IP
VTRS
Relative Strength Index (RSI) 24.41 37.87
Support Level N/A $9.82
Resistance Level $39.52 $16.38
Average True Range (ATR) 1.66 0.51
MACD -0.95 -0.28
Stochastic Oscillator 0.11 6.32

Price Performance

Historical Comparison
IP
VTRS

About IP International Paper Company

International Paper manufactures packaging products and cellulose fibers. It accounts for roughly one-third of the North American corrugated packaging market. The company also has a substantial presence in Europe following its acquisition of DS Smith. International Paper serves a variety of end markets, including industrial, consumer products, and manufacturing.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: